Related Experiment Video
Updated: Aug 22, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Interleukin-2-based therapies in cancer
Miro E Raeber1, Dilara Sahin1, Onur Boyman1,2
1Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
New interleukin-2 (IL-2) therapies are emerging for cancer treatment. These advanced formulations offer targeted delivery and receptor bias, improving the efficacy and safety of IL-2 immunotherapy.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Interleukin-2 (IL-2) is a cytokine with a critical role in immune responses.
- Understanding IL-2's dual effects (beneficial and adverse) is key to optimizing its therapeutic use.
- Previous IL-2 therapies faced limitations due to toxicity and lack of specificity.
Purpose of the Study:
- To review molecular insights into IL-2 mechanisms.
- To highlight the development of novel IL-2 formulations.
- To discuss the potential of these advanced IL-2 compounds in cancer immunotherapy.
Main Methods:
- Review of preclinical and clinical data on IL-2 formulations.
- Analysis of molecular mechanisms underlying IL-2 action.
- Evaluation of receptor bias and tissue-targeting strategies.
Main Results:
- Development of IL-2 formulations with enhanced receptor bias.
- Improved tissue-targeting properties leading to reduced off-target effects.
- Several new IL-2 compounds are progressing through clinical trials.
Conclusions:
- Molecular understanding has driven the creation of next-generation IL-2 therapies.
- These advanced IL-2 formulations represent a significant advancement in cancer immunotherapy.
- IL-2 therapy is entering a new era with improved safety and efficacy profiles.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers